Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study

Abstract Background To investigate the safety (adverse events [AEs] and post-vaccination multiple sclerosis [MS] activity within 6 weeks), clinical efficacy (protection against coronavirus disease 2019 [COVID-19]), and vaccine-induced humoral immunogenicity (SARS-CoV-2 neutralizing antibody, anti-nu...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Melika Jameie, Mehdi Azizmohammad Looha, Zahra Ebadi, Mobina Amanollahi, Kiana Amani, Fatemeh Nobahari, Alireza Abdollahi, Marziyeh Mousavi, Bahareh Pourghaz, Mohammad Hossein Harirchian
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2024-08-01
סדרה:	BMC Neurology
נושאים:	COVID-19 vaccines Multiple sclerosis BIBP COVID-19 vaccine Safety Vaccine efficacy “Immunity, Humoral”
גישה מקוונת:	https://doi.org/10.1186/s12883-024-03793-y
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!